Assessing the Effectiveness of Valbenazine in the Treatment of Tardive Dyskinesia as Determined by the AIMS and PGIC: Results from the KINECT 4 Trial

被引：0
|
作者：
Singer, C.
Comella, C.
Farahmand, K.
Burke, J.
Jimenez, R.
Siegert, S.
机构：
来源：
MOVEMENT DISORDERS | 2018年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
70
引用
收藏
页码：S33 / S33
页数：1
相关论文
共 50 条
  • [1] Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia: Additional Results From the KINECT 3 Study
    Correll, Christoph U.
    Cutler, Andrew J.
    Kane, John M.
    McEvoy, Joseph P.
    Liang, Grace S.
    O'Brien, Christopher F.
    JOURNAL OF CLINICAL PSYCHIATRY, 2019, 80 (01)
  • [2] Effects of Long-Term Valbenazine on Tardive Dyskinesia and Patient-Reported Outcomes: Results from the KINECT 4 Study
    Factor, Stewart
    Kane, John
    Marder, Stephen
    Hauser, Robert
    Farahmand, Khodayar
    Jimenez, Roland
    Burke, Joshua
    Siegert, Scott
    Liang, Grace
    NEUROLOGY, 2018, 90
  • [3] Effects of Long-Term Valbenazine on Tardive Dyskinesia and Patient-Reported Outcomes: Results from the KINECT 4 Study
    Singer, Carlos
    Comella, Cynthia
    Lindenmayer, Jean-Pierre
    Farahmand, Khodayar
    Burke, Joshua
    Jimenez, Roland
    Siegert, Scott
    MOVEMENT DISORDERS, 2018, 33 : S19 - S19
  • [4] Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia
    Ganz, Michael L.
    Chavan, Ameya
    Dhanda, Rahul
    Serbin, Michael
    Yonan, Charles
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 103 - 113
  • [5] Kinect 4: A Phase 3, One-Year, Open-Label Trial of Valbenazine in Participants With Tardive Dyskinesia
    Marder, Stephen
    Kane, John
    Factor, Stewart
    Jimenez, Roland
    Thai-Cuarto, Dao
    Liang, Grace
    NEUROPSYCHOPHARMACOLOGY, 2017, 42 : S396 - S397
  • [6] Effects of Long-Term Valbenazine on Tardive Dyskinesia by Body Region: Shift Analyses of KINECT 4 Study Results
    Comella, C.
    Singer, C.
    Marder, S.
    Burke, J.
    Farahmand, K.
    Jimenez, R.
    Siegert, S.
    MOVEMENT DISORDERS, 2018, 33 : S37 - S37
  • [7] A Phase 2 Study of Valbenazine (NBI-98854) for Treatment of Tardive Dyskinesia: KINECT 2
    Factor, Stewart
    Hauser, Robert
    Mandri, Daniel
    Castro-Gayol, Julio
    Jimenez, Roland
    Siegert, Scott
    O'Brien, Christopher
    NEUROLOGY, 2016, 86
  • [8] The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study
    Factor, Stewart A.
    Remington, Gary
    Comella, Cynthia L.
    Correll, Christoph U.
    Burke, Joshua
    Jimenez, Roland
    Liang, Grace S.
    O'Brien, Christopher F.
    JOURNAL OF CLINICAL PSYCHIATRY, 2017, 78 (09) : 1344 - +
  • [9] KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia
    Hauser, Robert A.
    Factor, Stewart A.
    Marder, Stephen R.
    Knesevich, Mary Ann
    Ramirez, Paul M.
    Jimenez, Roland
    Burke, Joshua
    Liang, Grace S.
    O'Brien, Christopher F.
    AMERICAN JOURNAL OF PSYCHIATRY, 2017, 174 (05): : 476 - 484
  • [10] Patterns of Improvement in Tardive Dyskinesia: Post-Hoc Analysis of a Long-Term Study with Valbenazine (KINECT 4)
    Correll, Christoph U.
    Carmack, Tara
    Shah, Chirag
    Lundt, Leslie
    ANNALS OF NEUROLOGY, 2021, 90 : S148 - S149
12345